TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07855211: A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Partici

Sponsor: Biogen · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 69 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT07855211 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07855211 Rescue Dossier →